

<b>NCT ID</b>	NCT02668770
<b>Title</b>	Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
<b>Phase</b>	Phase 1
<b>Date Added</b>	2016-01-29
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, MGN1703
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02617277
<b>Title</b>	Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-30
<b>Location</b>	Colorado, United States Florida, United States Tennessee, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AZD1775, MEDI4736
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02608385
<b>Title</b>	Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-18
<b>Location</b>	Illinois, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	VAPER
<b>Title</b>	A study looking at using a vaccine and chemotherapy to treat advanced cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-17
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Celecoxib, Cyclophosphamide, imiquimod, vaccine
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02600949
<b>Title</b>	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-09

<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT02537418
<b>Title</b>	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-09-01
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	durvalumab, Tremelimumab, Imfinzi
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02499328
<b>Title</b>	Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2015-07-16
<b>Location</b>	Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AZD5069, AZD9150, MEDI4736, tremelimumab (treme)
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02484404
<b>Title</b>	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2015-06-29
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes

<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Cediranib, durvalumab, Olaparib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT02465060
<b>Title</b>	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
<b>Phase</b>	Phase 2
<b>Date Added</b>	2015-06-08
<b>Location</b>	Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico
<b>Prior IO Allowed</b>	Yes

<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT02453620
<b>Title</b>	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-05-25
<b>Location</b>	California, United States Connecticut, United States Maryland, United States Pennsylvania, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp